Trajectories of Glomerular Filtration Rate and Progression to End Stage Renal Disease After Kidney Transplantation

Kidney Transplant Failure Clinical Trial

— TRAJAKT  

Official title:

Multicenter International Observational Study to Identify eGFR Trajectories and Their Determinants, and to Build a Multidimensional Prediction System to Predict the Probabilities of Belonging to eGFR Trajectories

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04226859
• Other study ID #: TRAJAKT
• Status: Recruiting
• Start date: January 2000
• Est. completion date: June 2020

Study information

• Verified date: January 2020
• Source: Paris Translational Research Center for Organ Transplantation
• Contact: Alexandre Loupy, Professor
• Email: alexandre.loupy[@]inserm.fr
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The gold standard for characterizing chronic kidney disease (CKD) is the glomerular filtration rate (GFR), which is commonly estimated in both native and transplanted kidneys for patient monitoring and therapeutic management and ultimately guides decision-making about whether a patient needs renal replacement therapy. In particular, the National Kidney Foundation has defined CKD stages according to estimated GFR (eGFR) values and in several studies, the eGFR slope or change has been found to be strongly associated with end stage renal disease (ESRD).

However, little is known about the heterogeneity of eGFR evolution in time - i.e. eGFR trajectories - and the related progression to ESRD and death. To date, no studies have investigated eGFR trajectories in diversified cohorts and populations worldwide, although this approach could provide a better understanding of CKD evolution and hence improve risk stratification. In addition, determinants of eGFR trajectories remain poorly described.

An unsupervised approach could allow examining eGFR trajectories over time and could lead to the identification of patient groups according to the probability of the progression of their kidney disease.

Therefore, this study aims:

1. To identify the long-term eGFR trajectories after kidney transplantation using latent class mixed models;

2. To identify the clinical, immunological, histological and functional determinants of the eGFR trajectories using multinomial regressions;

3. To investigate the associations of the eGFR trajectories with the progression to ESRD and death.

Based on the results, the investigators will provide an easily accessible tool to calculate personalized probabilities of belonging to eGFR trajectories after kidney transplantation, by using datasets from prospective cohorts and post hoc analysis of randomized control trial datasets.

Description:

Background

Chronic kidney disease (CKD) now affects 850 million individuals worldwide, exceeding the global prevalence of diabetes, cancer and HIV/AIDS. In addition, end-stage renal disease affects 7.4 million individuals and mortality rate for individuals burdened by kidney disease is now estimated at 5 to 10 million individuals each year. Therefore, developing better diagnostic and treatment approaches for the kidney disease epidemic is a global priority, as leading professional societies and health agencies have emphasized (the US Food & Drug Administration, the National Kidney Foundation, the European Medicines Agency, the European Society of Organ Transplantation, the American Society for Transplantation and the American Society of Transplant Surgeons).

However, current approaches for investigating the relationship between eGFR course and outcomes such as ESRD and mortality have been limited by registries with an overall lack on granular data, including infrequent eGFR measurements for a single patient and convenience clinical samples. An unsupervised longitudinal approach to determine patient eGFR evolution may bring an original perspective to the traditional clinical interpretation of kidney function based on limited eGFR measurements, short-term follow-up, and standard statistical approach.

Main Outcome(s) and Measure(s)

• eGFR trajectories

• Determinants of eGFR trajectories

• Associations of eGFR trajectories with ESRD and death

• Prediction system that will provide the personalized probabilities of belonging to eGFR trajectories

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 14000
• Est. completion date: June 2020
• Est. primary completion date: June 2020
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Kidney recipients transplanted after 2000

• Kidney recipients over 18 years of age

• Kidney recipients with at least two eGFR measurements after transplantation

Exclusion Criteria:

• Combined transplantation

Related Conditions & MeSH terms

• Kidney Function Issue
• Kidney Transplant Failure

Intervention

Other:
• No intervention
Kidney recipients aged over 18 and of all sexes recruited from 2000 in European and North American centers, who have eGFR follow-up and data from protocol and for cause biopsies available for allograft survival assessment; Randomized controlled trials conducted over the past 20 years with available data on protocol biopsy within the first year and follow up clinical, biological and histological data.

Locations

Country	Name	City	State
Belgium	Department of Nephrology and Renal Transplantation, University Hospitals Leuven	Leuven
Croatia	Department of Nephrology, Arterial Hypertension, Dialysis and Transplantation, University Hospital Centre Zagreb, School od Medicine University of Zagreb	Zagreb
France	Department of Nephrology, Centre Hospitalier Universitaire de Montpellier	Montpellier
France	Nephrology Dialysis Transplantation Department, University of Lorraine, Centre Hospitalier Universitaire de Nancy	Nancy
France	Centre Hospitalier Universitaire de Nantes	Nantes
France	Kidney Transplant Department, Necker Hospital, Assistance Publique - Hôpitaux de Paris	Paris
France	Kidney Transplant Department, Saint-Louis Hospital, Assistance Publique - Hôpitaux de Paris	Paris
France	Department of Transplantation, Nephrology and Clinical Immunology, Hôpital Foch	Suresnes
France	Department of Nephrology and Organ Transplantation, Centre Hospitalier Universitaire Rangueil	Toulouse
France	Bretonneau Hospital, Nephrology and Immunology Department	Tours
United States	Department of Surgery, Johns Hopkins University School of Medicine	Baltimore	Maryland
United States	Department of Medicine, Division of Nephrology, Comprehensive Transplant Center, Cedars Sinai Medical Center	Los Angeles	California
United States	Albert Einstein College of Medicine, Renal Division Montefiore Medical Center, Kidney Transplantation Program	New York	New York
United States	Virginia Commonwealth University School of Medicine	Richmond	Virginia
United States	William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic	Rochester	Minnesota

Sponsors (1)

Lead Sponsor	Collaborator
Paris Translational Research Center for Organ Transplantation

Countries where clinical trial is conducted

United States,  Belgium,  Croatia,  France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	eGFR trajectories	eGFR trajectories probabilities, calculated from a prediction system (based on clinical, histological, immunological, and functional factors) assessed at 1-year post transplantation.	Up to 10 years after kidney transplantation

External Links

•   Paris Transplant Group Website